Clinical trials: Moderate to Severe Ulcerative Colitis
Ulcerative Colitis (UC), Severe Ulcerative Colitis
A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body…
- Conditions
- Ulcerative Colitis (UC), Severe Ulcerative Colitis, Moderate Ulcerative Colitis
- Trial name
- ASCENTRA-UC (NCT07845487)
- Testing
- PALI-2108
- Where
- 115 sites in United States, Canada and 10 more
- Volunteers
- 204 people
- Sponsor
- Palisade Bio
Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC).
- Conditions
- Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
- Trial name
- EMERALD-3 (NCT07415044)
- Testing
- LY4268989
- Where
- 258 sites in United States, Argentina and 26 more
- Volunteers
- 1,431 people
- Sponsor
- Eli Lilly and Company
Moderate to Severe Ulcerative Colitis
A Study to Evaluate the Activity, and Safety of Vixarelimab in Participants With Moderate to Severe Active Ulcerative Colitis
This study aims to evaluate the pharmacodynamic (PD) effects of vixarelimab in the gut of participants with active moderate to severe ulcerative colitis (UC).
- Trial name
- NCT06693908
- Testing
- Vixarelimab
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Genentech, Inc.
Moderate to Severe Ulcerative Colitis
A Trial of HRS-7085 Tablets in Patients With Moderate to Severe Active Ulcerative Colitis
The study is being conducted to evaluate the safety, tolerability and pharmakokinetics of HRS-7085 in adults.
- Trial name
- NCT07760831
- Testing
- HRS-7085 tablets
- Where
- Moldova
- Volunteers
- 8 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Moderate to Severe Ulcerative Colitis
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis
This phase 2b study is designed to have all subjects go into a 12 week induction period to compare different doses of study drug against placebo.
- Trial name
- NCT04090411
- Testing
- Induction- PF-06480605 50 mg SC Q4W, Induction- PF-06480605 150 mg SC Q4W, Induction- PF-06480605 450 mg SC Q4W
- Where
- 166 sites in United States, Australia and 21 more
- Volunteers
- 246 people
- Sponsor
- Hoffmann-La Roche
Moderate to Severe Ulcerative Colitis
Study on Variation of Serum and Fecal Biomarkers After Treatment to Predict Mucosal Healing in Patients With Ulcerative Colitis
Mucosal healing is recognized hitherto as the best therapeutic endpoint in patients with Ulcerative Colitis (UC) but its use in daily practice is limited by the low acceptability of repeated colonoscopies.
- Trial name
- MIROIR (NCT07653750)
- Testing
- Serum and fecal measurements
- Where
- France
- Volunteers
- 62 people
- Sponsor
- University Hospital, Clermont-Ferrand
Moderate to Severe Ulcerative Colitis
Phase II Study of Hemay005 in Patients With Active Ulcerative Colitis
This study is a multicenter, randomized, double-blind study. There are three dosage groups: Hemay005 45 mg BID group, 60 mg BID group or placebo group, with 36 patients in each dosage group.
- Trial name
- NCT05486104
- Testing
- Hemay005 tablets
- Where
- 18 sites in China
- Volunteers
- 92 people
- Sponsor
- Ganzhou Hemay Pharmaceutical Co., Ltd
Moderate-to-severe Ulcerative Colitis, Crohn's Disease (CD)
Universal CAR-T Cell Injection Targeting CD19/BCMA in Patients With Inflammatory Bowel Disease
This is an open-label, Phase I, investigator-initiated trial (IIT) designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of RD06-05 in patients with moderate-to-severe ulcerative colitis…
- Trial name
- NCT07309744
- Testing
- RD06-05 CART Cell Infusion
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Evaluation of Safety, Efficacy, Pharmacokinetic and Pharmacodynamic of Bertilimumab in Patients With Active Moderate to Severe Ulcerative Colitis
This is a randomized, double blind, placebo-controlled, parallel group multi-center study in adult participants with active moderate to severe UC.
- Trial name
- NCT01671956
- Testing
- Bertilimumab
- Where
- 6 sites in Israel
- Volunteers
- 32 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Ulcerative Colitis, Ulcerative Colitis Chronic Moderate
Study of Novel Therapeutics for Acute Remedy of Colitis
This study is a clinical trial being done to investigate the efficacy of drug BRS201 as a treatment in patients with acute ulcerative colitis.
- Conditions
- Ulcerative Colitis, Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
- Trial name
- SHARC (NCT06420492)
- Testing
- BRS201
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Brigham and Women's Hospital
Moderate to Severe Ulcerative Colitis
A Study Assessing the Efficacy and Safety of CBP-307 in Subjects With Moderate to Severe Ulcerative Colitis (UC)
This study will evaluate the efficacy and safety of CBP-307 in subjects with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT04700449
- Testing
- Double-Blind 0.2mg CBP-307, Open-label CBP-307, Double-Blind 0.1mg CBP-307
- Where
- 66 sites in United States, China and 2 more
- Volunteers
- 145 people
- Sponsor
- Connect Biopharm LLC
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum for the Topical Treatment of Rectal Mucosal Ulcers
Ulcerative colitis (UC) is a chronic persistent inflammatory disease. The lesions are mainly confined to the large intestine and continuously affect the rectum and part or all of the colon.
- Conditions
- Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe, Rectal Ulcer
- Trial name
- NCT05912712
- Testing
- Autologous Platelet-rich Plasma (PRP) and Thrombin Coagulum Treatment, Autologous Platelet-poor Plasma (PPP) and Thrombin Coagulum Treatment, Mesalazine Suppository Treatment
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Xijing Hospital of Digestive Diseases
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
The purpose of the study is to evaluate the safety, tolerability, and clinical efficacy of PN-943 450 mg twice daily [BID] and PN-943 150 mg BID, compared with placebo BID, in subjects with moderate to severe active Ulcerative…
- Trial name
- NCT04504383
- Testing
- PN-943
- Where
- 122 sites in United States, Austria and 11 more
- Volunteers
- 169 people
- Sponsor
- Protagonist Therapeutics, Inc.
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Comparison Between Bowel Ultrasound-based Treat to Target Versus Routine Treat to Target Strategies in Ulcerative Colitis
UC (UC) is a chronic, relapsing and destructive inflammatory disorder of the colon which can lead to organ damage and impair quality of life.
- Trial name
- NCT05735665
- Testing
- bowel ultrasound, colonoscopy
- Where
- Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS San Raffaele
Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe
Study of OST-122 in Patients With Moderate to Severe Ulcerative Colitis
A Phase Ib/IIa to evaluate the safety and tolerability of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis over 28 days.
- Trial name
- NCT04353791
- Testing
- OST-122
- Where
- 16 sites in Spain, Ukraine
- Volunteers
- 32 people
- Sponsor
- Oncostellae S.L
Moderate to Severe Ulcerative Colitis
A Cohort Study Comparing IFX to CS for Moderate to Severe UC
The first-line treatment strategy of moderate to severe UC was a important question at issue. The biological agents had potentiality to alter the disease course of UC.
- Trial name
- INSURE (NCT04879966)
- Testing
- Infliximab, Corticosteroid
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
TD-1473 for Active Ulcerative Colitis (UC)
This study is designed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TD-1473 in subjects with moderately-to-severely active UC over 28 days.
- Trial name
- NCT02818686
- Testing
- TD-1473
- Where
- 8 sites in United States, Georgia and 2 more
- Volunteers
- 40 people
- Sponsor
- Theravance Biopharma
Moderate to Severe Ulcerative Colitis
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
The purpose of this study is to evaluate the efficacy and safety of itacitinib in participants with moderate to severe ulcerative colitis (UC).
- Trial name
- NCT03627052
- Testing
- Itacitinib
- Sponsor
- Incyte Corporation
Moderate to Severe Ulcerative Colitis
Fecal Calprotectin Levels, Quality of Life, and Workability in Patients Suffering From Ulcerative Colitis Under Adalimumab Therapy - AdaProQuo
The objectives of this study are to explore the fecal calprotectin (fC) levels of UC patients under adalimumab therapy and the correlation with their general wellbeing (Quality of Life [QoL]), workability, and disease activity.
- Trial name
- AdaProQuo (NCT02092389)
- Volunteers
- 10 people
- Sponsor
- AbbVie